Navigation Links
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
Date:10/10/2007

as Taxotere remain the primary therapy for the treatment of most solid tumors, and we know from preclinical models that MGCD0103 is synergistic with Taxotere and could potentially sensitize and re-sensitize patients to microtubule-targeted therapy. Because MGCD0103 is an isotype-selective HDACi, rather than a broad spectrum HDACi, it targets specific isotypes likely relevant to cancer, with potential reduction in off-target toxicity. This may be particularly important as we combine MGCD0103 with cytotoxic chemotherapy."

"We are delighted to be participating in this trial of docetaxel plus MGCD0103," commented Dr. Keith Flaherty, Associate Professor of Medicine, Abramson Cancer Center of the University of Pennsylvania Health System and a principal investigator for this trial. "MGCD0103 has shown significant activity in preclinical models, as well as objective responses in ongoing clinical trials. This clinical study will help build an understanding of the role of HDAC inhibitors in the treatment of solid tumors for which docetaxel remains an important standard treatment, an area of great interest to the research and clinical community."

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. Preclinical data suggest that the Class I HDAC isotypes targeted by MGCD0103 are important in cancer biology and, consequently, such selective HDAC inhibitors may have increased efficacy and reduced toxicity compared to non- selective inhibitors. MGCD0103 is being investigated as a single agent and in combination with other anticancer therapies in the treatment of a variety of hematological malignancies and solid tumors. MGCD0103 is currently being studied in clinical trials including Hodgkin's lymphoma, non-Hodgkin's lymphoma (NHL), myelodysplastic syndromes (MDS), acute myelogenous leukemia (AML), and pancreatic cancer as either a single agent or in combination with anticancer therapies.

MGCD0103 has received orphan drug des
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... -- Haemonetics Corporation (NYSE: HAE ) announced today that ... present at The East Coast IDEAS Investor Conference in ... , 2015 at 2:30pm Eastern time.  ... webcast at: http://www.wsw.com/webcast/threepa16/hae About ... global healthcare company dedicated to providing innovative blood management ...
(Date:5/26/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) today announced that ... The 2015 Jefferies Healthcare Conference in New ... for 3:00 pm EDT (12:00 noon PDT) Tuesday, June 2, ... Conference in New York City.  The presentation at the JMP ... Wednesday, June 24, 2015. Both presentations will be ...
(Date:5/26/2015)... , England and PITTSBURGH , May ... a leading global pharmaceutical company, today announced that Mylan ... the Bernstein Strategic Decisions Conference, Friday, May 29, 2015 ... can access a live webcast of the presentation via ... http://mylan.com/investors . An archived version will also be available ...
Breaking Medicine Technology:Depomed To Present At Healthcare Conferences In June 2
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) today announced ... at upcoming major medical meetings. The,data will ... QUADRAMET(R),(samarium Sm-153 lexidronam injection) in combination settings ... from prostate,cancer and multiple myeloma, as well ...
... of,In-Segment Late Loss, Non-Inferiority in Major Secondary Endpoint,of Target ... in the SPIRIT III U.S. Trial -, ABBOTT PARK, ... Abbott's SPIRIT III U.S. pivotal clinical,trial at the of ... following key results: , , -- ...
Cached Medicine Technology:New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 2New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 3New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 4New Clinical Data for Cytogen's Quadramet and Prostacint to be,Reported at Upcoming Major Medical Meetings 5Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 2Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 3Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 4Abbott's Xience V Everolimus Eluting Coronary Stent Superior to,Taxus Stent in Spirit III U.S. Pivotal Clinical Trial 5
(Date:5/26/2015)... Octo Consulting Group (Octo), an award-winning ... to the federal marketplace, has named Gaurav “GP” Pal ... this newly created role, Pal will be responsible for ... computing, big data, and digital services. , “We’re excited ... we continue to bring clients new and innovative solutions ...
(Date:5/26/2015)... May 26, 2015 Relias Learning ... for the health and human services market, announces expansion ... demand. After strong attendance and participation in 2014, they ... give their annual user conference an exciting new facelift. ... to come together and discuss best practices, share their ...
(Date:5/26/2015)... Pasadena, CA (PRWEB) May 26, 2015 ... is now offering complimentary dental cleanings with cosmetic treatments. ... , Cosmetic Dentistry , “We are committed ... giving you cutting-edge technology, outstanding customer service and a ... not only to change your smiles but to change ...
(Date:5/26/2015)... National Prevention Week , National Prevention Week ... supported by the Substance Abuse and Mental Health Services ... and action about, substance abuse as well as mental ... encouraged to join in promoting prevention strategies, in educating ... in building community partnerships. , The Voice of One, ...
(Date:5/26/2015)... York, NY (PRWEB) May 26, 2015 Award-winning ... for a good cause. "The photography show will connect viewers ... in their lives.” For the last five years, Raul has ... to convey the notion that we are not bounded by ... a language spoken in Raul’s native country, Bolivia. The photo ...
Breaking Medicine News(10 mins):Health News:Octo Consulting Group (Octo) Appoints Gaurav “GP” Pal as Vice President of Technology Strategy and Cloud Solutions 2Health News:Relias Learning Expands User Groups and Industry Influence 2Health News:Relias Learning Expands User Groups and Industry Influence 3Health News:Pasadena Porcelain Veneers Expert, Marine Martirosyan DDS, is Now Offering Complimentary Dental Cleaning with Cosmetic Treatments 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2
... Time" a Valuable Present: Peake, WASHINGTON, Dec. 21 ... volunteers who remember our nation,s,veterans, especially those hospitalized in ... "Some of our patients will be unable to ... B. Peake, Secretary of Veterans Affairs. "The,good cheer and ...
... research suggests , FRIDAY, Dec. 21 (HealthDay News) -- Treating ... concludes a University of Pennsylvania School of Medicine study in ... , It found that providing depression care management to older ... over five years by about 50 percent. , "Depression is ...
... for ambulatory care ... ... Cardiac Science,Corporation, (Nasdaq: CSCX ), a leading provider of ... of its HeartCentrix(R) ECG informatics software with Greenway,Medical Technology,s PrimeSuite(R) ...
... Milk Processors and, Bally Total Fitness to Shape Up ... ... SILVER SPRING, Md., Dec. 21 Discovery Health,s fifth,annual NATIONAL ... biggest and best year yet, with online registration beginning on,December ...
... costs of providing comprehensive screening and diagnostic services to ... or cervical cancer for treatment. Dr. Donatus U. Ekwueme ... Health Promotion at the Centers for Disease Control and ... cost of screening a woman for breast cancer was ...
... 20 ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), ... Drug,Application (NDA) to the U.S. Food and Drug ... seeking approval for Xibrom QD,as a treatment for ... (bromfenac ophthalmic solution), Xibrom is a topical ...
Cached Medicine News:Health News:VA Salutes Volunteers' Spreading Holiday Cheer 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 2Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 3Health News:Cardiac Science Announces HeartCentrix(R) ECG Informatics Connectivity With Greenway(R) Medical Technologies 4Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 2Health News:Discovery Health's Fifth Annual National Body Challenge Takes a Stand Against Obesity by Offering the Keys to Adopting a Healthy, Active Lifestyle 3Health News:Study determines costs of breast and cervical cancer detection among low-income women 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2
... Ergonomic Design for Unparalleled Comfort Pick one ... the balance. Notice the trigger and ejector positionsright ... because our pipettors are ergonomically designed to help ... of pipetting. Productivity In The Palm Of ...
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... Pick one of our pipettors up and ... and ejector positionsright where they should beeven if ... designed to help avoid repetitive stress injuries caused ... The Palm Of Your Hand Start dispensing ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: